UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)May 18, 2016
VYSTAR CORPORATION |
(Exact name of registrant as specified in its charter |
Georgia | 000-53754 | 20-2027731 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
2484 Briarcliff Rd NE, #22, Suite 159, Atlanta, GA | 30329 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code(866) 674-5238
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a- 12 under the Exchange Act (17 CFR 240.14a- 12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 | Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On May 18, 2016, Keith D. Osborn, MD, age 59, joined the Board of Directors of Vystar Corporation.Dr. Osborn is a board-certified Orthopaedic Spine Surgeon with 30 years of experience after completing his Spine Fellowship at Harvard University. He received his medical degree from the University of Maryland School of Medicine and performed his residency at Harvard University and Johns Hopkins Hospital. Dr. Osborn currently specializes in Spinal Surgery at Resurgens Orthopaedics in Atlanta with a focus on adult spinal disorders and total disc arthroplasty.
In connection with his election to the Board of Directors, Dr. Osborn was granted options to acquire 500,000 shares of Common Stock of the Company at an option price of $.05 per share, the closing price of the Common Stock on the date of grant. Such options vest 25,000 quarterly beginning June 30, 2016, and continuing for each fiscal quarter thereafter for so long as Dr. Osborn remains in the continuous service of the Company as a director.
Item 9.01 | Financial Statements and Exhibits |
(d) | Exhibits |
99.1 | Press Release dated May 18, 2016, announcing the appointment of Keith D. Osborn, MD to the Board of Directors of Vystar Corporation. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VYSTAR CORPORATION | ||
May 20, 2016 | By: | /s/ William R. Doyle |
William R. Doyle Chairman, President and Chief Executive Officer |